• Glenmark Pharmaceuticals Ltd., of Mumbai, India, said the International Centre for Dispute Resolution ruled in Glenmark's favor on the arbitration claim filed in August 2011 against Napo Pharmaceuticals Inc., of San Francisco, seeking, among other things, a ruling that Glenmark's exclusive rights to develop, commercialize and distribute Crofelemer in 140 countries for treatment of diarrheal diseases includes the exclusive rights to distribute through relief agencies in those countries and an injunction prohibiting Napo from sharing confidential information concerning the manufacture of Crofelemer.